Translating basic science and clinical breakthroughs into language we all can understand
Thursday, April 13, 2017
Research Plug!
Hey there everyone,
Hope is a super powerful medicine - for both patients and their doctors. I am an advocate of clinical trials because in the 9 years I've been at WVCI - I've seen firsthand how research changes lives and the diseases we have been treating. I've had the blessing to be involved with ibrutinib, idelalisib, obinutuzumab since the very beginning and many more drugs - some of which we will be routinely using soon.
My research group put together this video and it packs a punch in 3 minutes. I hope you are all energized to go out there and talk to your providers about research options that might be right for you.
Thanks for watching
Wednesday, February 1, 2017
Selecting Therapy in CLL
The CLL landscape continues to change very quickly. I have previously written about picking a first line therapy, but my post from 2013 has become quickly outdated.
I recently had the opportunity to participate with a group called "Clinical Care Options" on a decision support tool that allows you to plug in a variety of variables that are central to picking out a treatment regimen and then seeing what therapy would be selected by a handful of experts.
To use the tool, you have to register for an account - but I thought it would be worth it for a number of patients who are at the point of picking out a particular therapy.
Here is a link to the tool
I also serve on the CLL Steering Committee for Medscape. We have recently conducted several taped interviews discussing how to pick therapy in both the front line and relapsed / refractory setting. Here again, you need to sign up for an account - but worth it if you want more color commentary regarding the tool outlined above.
Here is the link for the frontline video with me and Steve Coutre
Here is the link for the the relapsed / refractory video with Stephen Schuster, Matthew Davids and Amy Goodrich
I would like to predict that these will remain relevant tools for the foreseeable future but I am happy to report that they will only be valuable for another 12-24 months before the world changes again.
I tried to embed these tools directly on the blog but unfortunately was not able to do so. I hope you find them helpful.
Thanks for reading / viewing / tooling.
I recently had the opportunity to participate with a group called "Clinical Care Options" on a decision support tool that allows you to plug in a variety of variables that are central to picking out a treatment regimen and then seeing what therapy would be selected by a handful of experts.
To use the tool, you have to register for an account - but I thought it would be worth it for a number of patients who are at the point of picking out a particular therapy.
Here is a link to the tool
I also serve on the CLL Steering Committee for Medscape. We have recently conducted several taped interviews discussing how to pick therapy in both the front line and relapsed / refractory setting. Here again, you need to sign up for an account - but worth it if you want more color commentary regarding the tool outlined above.
Here is the link for the frontline video with me and Steve Coutre
Here is the link for the the relapsed / refractory video with Stephen Schuster, Matthew Davids and Amy Goodrich
I would like to predict that these will remain relevant tools for the foreseeable future but I am happy to report that they will only be valuable for another 12-24 months before the world changes again.
I tried to embed these tools directly on the blog but unfortunately was not able to do so. I hope you find them helpful.
Thanks for reading / viewing / tooling.
Thursday, May 12, 2016
The Improvisational Oncologist
I have been a big fan of Sid Mukherjee ever since we were om training together. I was a mere intern and he was a Jr. Resident but it is always fun to be in the presence of somebody who is really smart and really humble about it.
He went on to write, "The Emperor of all Maladies" which won the Pulitzer Prize and documents the history of cancer treatment. If you haven't read it, I highly recommend you read it or watch the six hour documentary that Ken Burns made out of it for PBS.
Sid wrote an article for the New York Times Magazine posted this weekend called "The Improvisational Oncologist." It is an informative read that describes some of the new medical adventures we have to take with our patients. If you haven't read it, I would encourage you to do so.
He went on to write, "The Emperor of all Maladies" which won the Pulitzer Prize and documents the history of cancer treatment. If you haven't read it, I highly recommend you read it or watch the six hour documentary that Ken Burns made out of it for PBS.
Sid wrote an article for the New York Times Magazine posted this weekend called "The Improvisational Oncologist." It is an informative read that describes some of the new medical adventures we have to take with our patients. If you haven't read it, I would encourage you to do so.
Wednesday, April 27, 2016
Venclexta
I have never before done a "guest post" on this blog, although I desperately need to do more of it. This year has been very productive for me publishing scientific papers and there is an incredible amount of work that goes into these efforts. Unfortunately, it has definitely distracted me quite a bit from doing any blog updates.
One of my favorite research colleagues - Tom Boyd from Yakima Washington has an enormous experience with venclexta. He has treated quite a few patients on research studies with the drug. I've treated several patients early on in the development. Unfortunately, shortly after we got started, there were two well documented episodes of fatal tumor lysis syndrome that occurred at other treating institutions that sadly took the lives of two brave research pioneers.
In my position leading a national research organization, I've done countless chart reviews, registry studies, protocol reviews, etc. I have gained a healthy respect for the ability of doctors to really mess things up. This drug is unique - the speed with which it works is almost unprecidented. The potential downside of that can be rapid biochemical shifts as cells die off that require additional medical caution. While the rate of "low grade" tumor lysis syndrome is about 4% in some studies, clinical trials provide rigorous oversight that may not be as available in the real world experience with the drug.
I am extremely pleased by the length to which Abbvie is extending support to treating doctors to ensure that the drug is used safely. I cannot recall a drug launch in which the pharmaceutical company made such a strong commitment to physician education. I would still encourage patients who are going to start this drug to read section 2.3 of the prescribing information. An educated patient can be an extra set of eyes on the data and provide an additional layer of safety.
In my position leading a national research organization, I've done countless chart reviews, registry studies, protocol reviews, etc. I have gained a healthy respect for the ability of doctors to really mess things up. This drug is unique - the speed with which it works is almost unprecidented. The potential downside of that can be rapid biochemical shifts as cells die off that require additional medical caution. While the rate of "low grade" tumor lysis syndrome is about 4% in some studies, clinical trials provide rigorous oversight that may not be as available in the real world experience with the drug.
I am extremely pleased by the length to which Abbvie is extending support to treating doctors to ensure that the drug is used safely. I cannot recall a drug launch in which the pharmaceutical company made such a strong commitment to physician education. I would still encourage patients who are going to start this drug to read section 2.3 of the prescribing information. An educated patient can be an extra set of eyes on the data and provide an additional layer of safety.
I asked Tom if he would be willing to put his thoughts about this drug into a post. 12 hours later he sent me this - thanks Tom. And oh yeah, by the way, happy birthday old man! Here is his post:
These are exciting and hopeful times for patients with CLL and
physicians treating CLL.
Dr. Sharman asked me to review some of my experience with the
recently approved drug VENCLEXTA (venetoclax). I have treated 10 patients with
this drug as part of an ongoing Genentech trial. This drug is also known as
venetoclax and ABT-199 (generic and research names). It has been under
development for about 10 years. The drug was co-developed with Abbvie and
Genentech.
The initial approval by the FDA on 4/11/16 was for patients with
the 17p deletion in chronic lymphocytic leukemia who have undergone at least
one prior therapy. At this point, it is only approved as a single
agent (not given with other drugs like Rituxan, chlorambucil or bendamustine).
Unlike other oral agents which the FDA recently approved (B-cell receptor drugs
such as ibrutinib and idelalisib), this drug works as a bcl-2 inhibitor.
What is bcl-2 and how does VENCLEXTA/venetoclax really work?
The term ‘bcl-2’ refers to an enzyme within the cancer cell that helps keep the cell alive. Almost all CLL cells have a
significant ‘overexpression’ of bcl-2. The bcl-2 family of proteins are located
in the mitochondria of all cells (including CLL cell). The mitochondria are the
energy producing structures which reside in the cytoplasm of all cells. That
‘overexpression’ of bcl-2 means the cells tend to live forever and don’t
undergo normal cell death. That is why the white blood count tends to rise and
the lymph nodes enlarge steadily during ‘watch and wait.’
VENCLEXTA (ABT-199) is a selective oral medication which inhibits bcl-2. As a result of exposure of CLL cells to VENCLEXTA, there is almost
always a rapid apoptosis (rapid death of CLL cells). Most CLL cells have
a significant imbalance in their bcl-2 proteins in the mitochondria. There is
an interesting video showing the way we believe that VENCLEXTA works on
microscopic level (https://www.youtube.com/watch?v=OGvIlvH-ke4).
What does the recent approval mean to patients with CLL?
Since the 17-p deletion only occurs in a small percentage of
patients with early CLL, it will have limited use for most patients at this
time. If you either have a 17-p deletion at diagnosis (~10% chance) or
developed it later on (up to 40% chance), there is a good chance your doctor
may consider the option of treatment with VENCLEXTA. In order to receive this
drug you will have to have had one or more prior treatments.
Your doctor will have to consider all the options which are
useful in patients with CLL and the 17-p deletion. Currently, ibrutinib is the
most commonly used medication. Many clinical trials with ibrutinib, ACP-196 and
ABT-199 are actively studying patients with this high risk mutations. Some of
these studies also incorporate drugs such as Rituxan, Gazyva or bendamustine.
If your doctor believes that you are a candidate for VENCLEXTA,
your would need to undergo a number of lab tests, scans to look at the lymph
node & spleen size and finally a bone marrow exam. If you have a great deal
of disease (high white count, very large lymph node, a big spleen and a
‘packed’ bone marrow), then the risks associated with treatment may be much
higher. Some patients with higher risk for tumor lysis will need to spend time
in the hospital during their initial therapy. Many of the clinical trials for
this drug required admission to a hospital for initiation of treatment.
Overall, the treatment with VENCLEXTA has been very well
tolerated in research studies, with many patients now on therapy for over two
years. However, the initial management (first month of treatment) can be
associated with tumor lysis syndrome. That syndrome lead to some deaths
and kidney dialysis in the early trials with VENCLEXTA (ABT-199). Therefore the
attention and care in starting this drug is MUCH MORE complicated than other
oral treatments for CLL. Dr. Sharman discusses the issue of tumor lysis elsewhere.
Should I run off to the nearest major cancer center to be
treated with this new agent?
If you do not have the 17-p deletion mutation, then at this time
you could only receive this drug, except as part of a clinical trial. However,
as with ibrutinib, the indications for treatment will likely broaden to other
groups of patients with relapsed (previously treated) and untreated CLL. It is
very likely that you will have this treatment option in the next year or two.
If you have been previously treated and you have the 17-p deletion, then you might be a good candidate for treatment with VENCLEXTA. At
this point, very few physicians have a lot of experience with this drug. Both
Dr. Sharman and I are concerned about the use of this drug by inexperienced
physicians and centers. Very careful lab monitoring, hydration and treatment
for uric acid levels are critical. You might consider a second opinion before
starting this drug, if your situation allows.
If you and your doctor decide to start treatment with VENCLEXTA,
then i would encourage you to carefully read everything you can about this
agent to understand all the safety issues including a knowledge of tumor lysis syndrome.
Which doctors should treat CLL patients with this new drug?
Technically almost any cancer doctor can write a prescription for
this drug. I would strongly recommend that only a doctor who is experienced in
CLL treatments should be managing the initial month of therapy. Once the drug
is escalated up to full dose than most cancer doctors could easily follow you
for longer term monitoring.
How is this oral drug different than ibrutinib? Is it better,
safer and better tolerated?
Both ibrutinib and venetoclax are oral drugs. They work in
different ways to kill and inhibit CLL cells. As we discussed above, the
veneotoclax tends to kill CLL cells quickly and the WBC in many trials is
essentially normal within a month. Ibrutinib, on the other hand, results in
‘re-distrubution’ of CLL cells with a rising white count over the first month
in most patients. Both drugs result in fairly rapid shrink in the enlarged
lymph nodes. VENCLEXTA seems to produce deeper remissions (‘MRD negative’ blood
and bone marrow tests).
Sides effects with VENCLEXTA include neutropenia (low white
count), anemia and low platelet count. Intestinal symptoms were also fairly
common, but could be controlled with lower doses. Most people are able to carry
on normal activities. Side effects with ibrutinib include easy bleeding and
atrial fibrillation (irregular heart beat).
We do not yet know how long to treat patients with ibrutinib and
VENCLEXTA. Dr.Sharman and I both have patients who has been doing well on
ibrutinib for over 6 years. A number of patients have been on continous
VENCLEXTA for over two years.
If I have a 17p deletion in my CLL how quickly does therapy
need to be started?
Some patients may require treatment fairly quickly, but in most
cases, reviewing you options and deciding about treatment might go on for a
couple months. Some cases of CLL and 17-p deletion will only progress slowly,
giving you and your doctor lots of time to look at all the choices carefully
(bcl-2 inhibitors, ibrutinib, antibodies and chemotherapy).
If I have a 17p deletion which drug should my doctor be using
ibrutinib, acalabrutinib, ldelalisib, or venetoclax?
The good news is that all of these drugs represent major
improvements in treatment of 17-p deleted CLL compared to 5 years ago. Your
best choice will likely depend on your other medical conditions. Your doctor
may be influenced by heart disease, bleeding risk, use of anticoagulants, …..
Your insurance may require you to start with one of these agents initially.
Your concern about the small, but very real risk of TLS may affect your
choices.
If I do not have 17p deletion can I receive this drug? What if
I have other higher risk genetic changes such as 11q deletion or and un-mutated
IGHV?
There are a number of active trials looking at use of VENCLEXTA
either alone or in combination for other patients with CLL (not just 17p
deleted). As mentioned above, if you don’t require treatment immediately, then
several additional treatment options with VENCLEXTA and other agents may become
available in the next 1-2 years.
What would I do if I had CLL right now?
This is always a tough question to throw back at your doctor.
There are so many choices with CLL that it can even be confusing for
Hematologists. I just turned 63 years old last week, so I am a very typical age
for the initial diagnosis of CLL [but, Dr. Sharman has yet to send me a
birthday card ;-) …].
If I had low risk disease that required treatment, then
many choices may be very good options such as FCR, BR, and Gazyva (for example).
If there was a nearby trial for VENCLEXTA, I would try to learn more about it.
If I had higher risk disease (11q deletion or and unmutated IGVH)
then I would explore treatments with the agents such as ibrutinib or trials
which incorporated ACP-196 or VENCLEXTA.
If I had CLL with a 17-p deletion I would want to be sure my
treatment options included ibrutinib, ACP-196 and VENCLEXTA. We do not have any
direct comparisons between these agents, but I am impressed with the ‘depth of
response’ seen in many patients following treatment with VENCLEXTA alone or in
combination.
Tom Boyd
Monday, April 11, 2016
Venetoclax approved
Venetoclax has been approved!!!
Horray, just came out of a patients room and told her this would be approved by the next time I saw her. I guess I was wrong, it was already approved!
This is a fantastic drug and one of the most effective agents ever in CLL. See the press release (click here). Several years ago, I wrote about BCL-2 as a target (click here)
I have written about tumor lysis previously (click here) and it is worth a read.
This drug is currently approved for patients with relapsed CLL that has 17P deletion - but like ibrutinib will become more and more available as new clinical trials read out.
More later if I can find time to post
Horray, just came out of a patients room and told her this would be approved by the next time I saw her. I guess I was wrong, it was already approved!
This is a fantastic drug and one of the most effective agents ever in CLL. See the press release (click here). Several years ago, I wrote about BCL-2 as a target (click here)
I have written about tumor lysis previously (click here) and it is worth a read.
This drug is currently approved for patients with relapsed CLL that has 17P deletion - but like ibrutinib will become more and more available as new clinical trials read out.
More later if I can find time to post
Thursday, March 17, 2016
Sunday, November 8, 2015
FCR: The Empire Strikes Back
I'm not really a huge Star Wars guy, but the title seemed appropriate for the content. For web savvy CLL patients FCR is a lot like the "evil empire." With two new papers on this regimen, FCR is making a strong push in selected patients.
If a patient was offered a huge likelihood of long term disease control (as in just about every patient would be disease free at 7-8 years post treatment) AND many of those long term remissions were actually looking a lot like cures - would you take FCR?
In today's CLL climate, web informed patients are rebelling against FCR - and in many cases, I think it is for good reason. FCR is a tough regimen. Even in the German CLL8 study, about 4% of patients die in the first 12 months after starting therapy. In the MD Anderson data set, it appears that unusual infections are increased as far out as two years from therapy. The long term risk of marrow compromise and secondary cancers is real.
But.... In appropriately selected patients, it is probably all worth it.
Two new data sets shed important new data on this regimen that is now almost 15 years old. An update from the MD Anderson group shows that patients with IgHV mutated CLL have impressive median progression free survival in excess of 12.8 years and that no relapses happened in any patients who made it to 10 years (in other words - if you made it 10 years, you appear to be free and clear). The numbers were comparatively poor however for those patients with IgHV unmutated CLL. This test should be absolutely CENTRAL to the management of CLL patients being considered for aggressive chemoimmunotherapy - but unfortunately we have data to show that the test is woefully underperformed.
The German group has updated their analysis of the FC vs FCR study with a focus on cytogenetic risk groups with best outcomes. They validate the role of IgHV status with incredible rates of long term disease control in patients with IgHV mutated CLL particularly those lacking 17P. For those patients with trisomy 12 not a single patient experienced progression and the del 13Q folks did extremely well too. I talked with Stilgenbauer recently and he is still reticent to use the word CURE, but I think these subgroups (IgVH mutated WITH either Trisomy 12, or Del 13Q) have high likelihood of super long term disease control if not cure.
None the less, FCR is clearly not for everyone. If you look at inclusion criteria for FCR studies, only a small number of "typical" CLL patients would be considered eligible. Furthermore, from the German CLL10 study, we know that the benefit of FCR over BR is primarily in those patients less than age 65. The median age of frontline treatment in the US is closer to 72. I will be eager to see subsequent analysis looking at FCR in patients above age 65 who have the favorable marker profile - that remains a question mark for me.
SO... to summarize
For patients with CLL who need therapy, it is imperative to test for FISH and for anyone considering intensive chemoimmunotherapy - IgHV mutation analysis is a must. For patients less than age 65 with IgHV mutated CLL and either trisomy 12 or del 13Q, should seriously consider FCR as these groups have exceptionally high rates of progression free survival (like about 90% and I believe many of these will prove to be cured).
While FCR has been pushed back in the minds of many following the introduction of novel agents, this small subgroup has results that may help best define the "home" for FCR.
That doesn't answer what to do for those patients with IgHV unmutated CLL, but in my own mind, the long term outcome of FCR in this population (provided there is no 17P deletion) is considerably less favorable and I tend to prefer bendamustine based regimens. While FCR may still have better "frontline" outcomes than BR in patients less than age 65 according to CLL10, BR is clearly a lot easier to tolerate and I expect lower long term toxicity. Because our options in relapsed CLL are so darn good, not sure you need the incremental benefit of FCR in the frontline if it really beats up your marrow for the future.
The German "GREEN" study of Bendamustine with obinutuzumab has reported really excellent results with the swapping of rituximab for obinutuzumab and is something we are researching within US Oncology. Obviously any opportunity to add a novel targeted agent (BTK, PI3K, BCL-2) to this regimen would be great, but currently those combinations have not been approved and are not available outside of a clinical trial.
Anyhow, wanted to get a blog post up. It has been way too long. Lots of stuff happening in my own life that has me busier than ever. Getting an hour here and there for a blog post is a rarity these days. Hopefully this is still valuable.
To leave a comment, click on the title of this post then scroll down to the bottom. There should be a place to enter comments.
If a patient was offered a huge likelihood of long term disease control (as in just about every patient would be disease free at 7-8 years post treatment) AND many of those long term remissions were actually looking a lot like cures - would you take FCR?
In today's CLL climate, web informed patients are rebelling against FCR - and in many cases, I think it is for good reason. FCR is a tough regimen. Even in the German CLL8 study, about 4% of patients die in the first 12 months after starting therapy. In the MD Anderson data set, it appears that unusual infections are increased as far out as two years from therapy. The long term risk of marrow compromise and secondary cancers is real.
But.... In appropriately selected patients, it is probably all worth it.
Two new data sets shed important new data on this regimen that is now almost 15 years old. An update from the MD Anderson group shows that patients with IgHV mutated CLL have impressive median progression free survival in excess of 12.8 years and that no relapses happened in any patients who made it to 10 years (in other words - if you made it 10 years, you appear to be free and clear). The numbers were comparatively poor however for those patients with IgHV unmutated CLL. This test should be absolutely CENTRAL to the management of CLL patients being considered for aggressive chemoimmunotherapy - but unfortunately we have data to show that the test is woefully underperformed.
The German group has updated their analysis of the FC vs FCR study with a focus on cytogenetic risk groups with best outcomes. They validate the role of IgHV status with incredible rates of long term disease control in patients with IgHV mutated CLL particularly those lacking 17P. For those patients with trisomy 12 not a single patient experienced progression and the del 13Q folks did extremely well too. I talked with Stilgenbauer recently and he is still reticent to use the word CURE, but I think these subgroups (IgVH mutated WITH either Trisomy 12, or Del 13Q) have high likelihood of super long term disease control if not cure.
None the less, FCR is clearly not for everyone. If you look at inclusion criteria for FCR studies, only a small number of "typical" CLL patients would be considered eligible. Furthermore, from the German CLL10 study, we know that the benefit of FCR over BR is primarily in those patients less than age 65. The median age of frontline treatment in the US is closer to 72. I will be eager to see subsequent analysis looking at FCR in patients above age 65 who have the favorable marker profile - that remains a question mark for me.
SO... to summarize
For patients with CLL who need therapy, it is imperative to test for FISH and for anyone considering intensive chemoimmunotherapy - IgHV mutation analysis is a must. For patients less than age 65 with IgHV mutated CLL and either trisomy 12 or del 13Q, should seriously consider FCR as these groups have exceptionally high rates of progression free survival (like about 90% and I believe many of these will prove to be cured).
While FCR has been pushed back in the minds of many following the introduction of novel agents, this small subgroup has results that may help best define the "home" for FCR.
That doesn't answer what to do for those patients with IgHV unmutated CLL, but in my own mind, the long term outcome of FCR in this population (provided there is no 17P deletion) is considerably less favorable and I tend to prefer bendamustine based regimens. While FCR may still have better "frontline" outcomes than BR in patients less than age 65 according to CLL10, BR is clearly a lot easier to tolerate and I expect lower long term toxicity. Because our options in relapsed CLL are so darn good, not sure you need the incremental benefit of FCR in the frontline if it really beats up your marrow for the future.
The German "GREEN" study of Bendamustine with obinutuzumab has reported really excellent results with the swapping of rituximab for obinutuzumab and is something we are researching within US Oncology. Obviously any opportunity to add a novel targeted agent (BTK, PI3K, BCL-2) to this regimen would be great, but currently those combinations have not been approved and are not available outside of a clinical trial.
Anyhow, wanted to get a blog post up. It has been way too long. Lots of stuff happening in my own life that has me busier than ever. Getting an hour here and there for a blog post is a rarity these days. Hopefully this is still valuable.
To leave a comment, click on the title of this post then scroll down to the bottom. There should be a place to enter comments.
Thursday, June 4, 2015
Frontline Survival Benefit for Ibrutinib
NEWSFLASH:
Resonate-2, the randomized phase III study comparing frontline ibrutinib against chlorambucil met its primary endpoint of progression free survival (how long you are both alive AND without progression) and ended early. More importantly, the secondary endpoint of overall survival was improved as well
Meeting the primary endpoint was a virtual certainty. Everybody knew this study would be positive - but the study had to be done in order to get FDA approval for frontline ibrutinib. Single agent chlorambucil is a dead dog. It has served as the control arm that has been beaten up by just about every new drug in CLL in the last ten years (including campath, bendamustine, fludarabine, obinutuzumab, and now ibrutinib).
Meeting the secondary endpoint is a little more provocative. This study was built with a crossover design - meaning if you were randomized to chlorambucil and experienced disease progression, they gave you ibrutinib at that point. If there is an overall survival benefit, it means that early ibrutinib saves lives compared to ibrutinib after progression. This was also true in the Resonate study comparing ibrutinib to ofatumumab and the Gilead study that led to approval of idelalisib in combination with rituximab. That is three studies that show that patients die faster when they get ineffective therapy compared to novel agents. It remains to be seen if that is true with standard regimens that actually work like bendamustine-rituximab or FCR where the bar will be much higher than chlorambucil.
Presumably this will be presented at ASH if it isn't already published by then. It will also lead to FDA approval of frontline ibrutinib but that is probably still a ways off and the exact prescribing "label" will determine who can get it in the frontline. I have no particular insight, but suspect that is still 4-8 months away.
There will be several key details I want to see in the presentation:
1) In this "elderly" subset of patients - how well was ibrutinib tolerated? In most clinical trials it appears that about 5-10% of patients discontinue drug for poor tolerance. Age has also been shown to be biggest variable leading to drug discontinuation - and the median age in this study is likely to be a fair bit higher than other studies due to the nature of the control arm
2) How good is good? Our group helped contribute to the "frontline ibrutinib" data published in the Lancet. In that cohort of about 40 patients, only one patient experienced disease progression and several others discontinued for intolerance. In this larger - multicenter study, it will be the largest to date of previously untreated patients to go on ibrutinib. Is the progression rate still that good? Are there more progressions or is it still in the low single digits?
3) What happens to patients who discontinue ibrutinib? In the relapsed / refractory setting, patients who discontinue ibrutinib have been extremely sick and many have died very quickly. There has been a fair bit of discussion about "ibrutinib discontinuation syndrome." Some have argued that these patients had already failed every other therapy which is why they died so quickly. In this treatment naïve cohort - that excuse cannot hold. If the overall survival curve looks like the progression free survival curve - I will be worried.
4) Dose intensity. Do patients start 3 pills per day and stay on three pills per day without dose reduction or interruption? The ASCO data just presented really gives me considerable apprehension about big dose interruptions. As a patient, I would be trying to keep skipped doses to a minimum. Obviously you may need to do that for surgery etc. but if I had the choice, I would not want to do that early in a treatment course when there are a lot more CLL cells running around.
5) Cytogenetics and high risk markers: While chlorambucil is such a dog it really isn't worthy of a comparison arm, it will be interesting to look at the subgroups treated on ibrutinib. While comparing across trials is always dangerous, we have expectations for the outcomes of patients with markers like TP53, 11Q, and IgHV mutated/unmutated. This will serve as some interesting food for thought with those higher risk populations.
This news release follows two positive randomized phase III trials presented at ASCO for ibrutinib in combination with bendamustine/rituximab and idelalisib in combination with ofatumumab. These latter two studies are important but may not have as much practice impact as the study discussed above.
With a frontline indication for ibrutinib likely available within a year, it begs the question who to treat with chemotherapy and who to treat with targeted agents. I've attached some slides from a talk I recently gave on this topic but please note that these reflect my approach and guidelines are rapidly changing in this disease.
Thanks for reading. To leave a comment, click on the title of this post and it will open up the post in a new window with a comment section at the bottom.
Resonate-2, the randomized phase III study comparing frontline ibrutinib against chlorambucil met its primary endpoint of progression free survival (how long you are both alive AND without progression) and ended early. More importantly, the secondary endpoint of overall survival was improved as well
Meeting the primary endpoint was a virtual certainty. Everybody knew this study would be positive - but the study had to be done in order to get FDA approval for frontline ibrutinib. Single agent chlorambucil is a dead dog. It has served as the control arm that has been beaten up by just about every new drug in CLL in the last ten years (including campath, bendamustine, fludarabine, obinutuzumab, and now ibrutinib).
Meeting the secondary endpoint is a little more provocative. This study was built with a crossover design - meaning if you were randomized to chlorambucil and experienced disease progression, they gave you ibrutinib at that point. If there is an overall survival benefit, it means that early ibrutinib saves lives compared to ibrutinib after progression. This was also true in the Resonate study comparing ibrutinib to ofatumumab and the Gilead study that led to approval of idelalisib in combination with rituximab. That is three studies that show that patients die faster when they get ineffective therapy compared to novel agents. It remains to be seen if that is true with standard regimens that actually work like bendamustine-rituximab or FCR where the bar will be much higher than chlorambucil.
Presumably this will be presented at ASH if it isn't already published by then. It will also lead to FDA approval of frontline ibrutinib but that is probably still a ways off and the exact prescribing "label" will determine who can get it in the frontline. I have no particular insight, but suspect that is still 4-8 months away.
There will be several key details I want to see in the presentation:
1) In this "elderly" subset of patients - how well was ibrutinib tolerated? In most clinical trials it appears that about 5-10% of patients discontinue drug for poor tolerance. Age has also been shown to be biggest variable leading to drug discontinuation - and the median age in this study is likely to be a fair bit higher than other studies due to the nature of the control arm
2) How good is good? Our group helped contribute to the "frontline ibrutinib" data published in the Lancet. In that cohort of about 40 patients, only one patient experienced disease progression and several others discontinued for intolerance. In this larger - multicenter study, it will be the largest to date of previously untreated patients to go on ibrutinib. Is the progression rate still that good? Are there more progressions or is it still in the low single digits?
3) What happens to patients who discontinue ibrutinib? In the relapsed / refractory setting, patients who discontinue ibrutinib have been extremely sick and many have died very quickly. There has been a fair bit of discussion about "ibrutinib discontinuation syndrome." Some have argued that these patients had already failed every other therapy which is why they died so quickly. In this treatment naïve cohort - that excuse cannot hold. If the overall survival curve looks like the progression free survival curve - I will be worried.
4) Dose intensity. Do patients start 3 pills per day and stay on three pills per day without dose reduction or interruption? The ASCO data just presented really gives me considerable apprehension about big dose interruptions. As a patient, I would be trying to keep skipped doses to a minimum. Obviously you may need to do that for surgery etc. but if I had the choice, I would not want to do that early in a treatment course when there are a lot more CLL cells running around.
5) Cytogenetics and high risk markers: While chlorambucil is such a dog it really isn't worthy of a comparison arm, it will be interesting to look at the subgroups treated on ibrutinib. While comparing across trials is always dangerous, we have expectations for the outcomes of patients with markers like TP53, 11Q, and IgHV mutated/unmutated. This will serve as some interesting food for thought with those higher risk populations.
This news release follows two positive randomized phase III trials presented at ASCO for ibrutinib in combination with bendamustine/rituximab and idelalisib in combination with ofatumumab. These latter two studies are important but may not have as much practice impact as the study discussed above.
With a frontline indication for ibrutinib likely available within a year, it begs the question who to treat with chemotherapy and who to treat with targeted agents. I've attached some slides from a talk I recently gave on this topic but please note that these reflect my approach and guidelines are rapidly changing in this disease.
Thanks for reading. To leave a comment, click on the title of this post and it will open up the post in a new window with a comment section at the bottom.
Sunday, May 17, 2015
Take your pills - ibrutinib dosing matters!
When we are investigating new drugs that have never been tested before, we start with what's called a phase 1 study. Historically, the goal of a phase 1 study was to define the "maximum tolerated dose." In the era of traditional cytotoxic chemotherapy, you knew you had arrived at that dose when patients simply couldn't handle any more - it was just to much. Perhaps they had too much nausea or vomiting, or the liver couldn't handle it anymore, kidneys failed, or some other toxicity made it clear that you had reached the limits of human tolerance. As researchers, we just hoped we could get the drug levels high enough without causing too much damage. If we achieved blood levels that we expected to kill the cancer cells without irreparably harming the patient in the process - that was victory.
Many of the new drugs challenge that paradigm. When treatments effectively target the specific molecular abnormality with a cancer cell we can see considerably more efficacy while at the same time reducing toxicity. This has led to the concept of "optimal biologic dose." Instead of pushing the dose to the max, you only increase the dose as far as you need to - often with substantially less side effects than the traditional therapies.
Unfortunately, "optimal biologic dose" is much harder to define than "maximum tolerated dose." It presumes that we have effective and accurate means of actually measuring what were trying to do. While it may come as a surprise to many patients, the unfortunate reality is that there is an enormous amount of human judgment as well as a paucity of clear data involved in early clinical trials. Things are not as scientifically certain in early trials compared to the level of data we have later in a drugs like cycle. Furthermore, we often need to generalize to the larger population from a very small subset of patients that are appropriate for a phase I study.
There is new data regarding the dosing of Ibrutinib that I think is really important to consider.
Most drugs inhibit enzymes in what we call a "reversible" fashion. This means that the particular target is turned off only when you have high enough levels of the drug in the blood. Ibrutinib is a little bit different, it is what we call a "covalent" inhibitor. When you swallow a pill of Ibrutinib it gets into the bloodstream and either quickly binds to the BTK protein or it gets eliminated from the body. Within just a few hours of taking a pill there is virtually no free drug in the blood. Instead, it is all bound to the BTK protein - completely shutting down that signaling pathway until the cell makes more BTK. This is very different than most oral drugs where we are trying to make sure the levels are still high enough right before you take your next dose.
When you had a sore throat as a kid, the doctor always said to be sure to take all your pills so that the bacteria didn't become resistant. It is virtually a scientific paradigm that exposing bacteria to inadequate antibiotic dosing creates resistance. The same is probably true in leukemia and lymphoma with some of the new drugs. A CLL cell that has its B-cell receptor signaling pathway completely inhibited has a hard time escaping that inhibition. If that same pathway is only partially inhibited however, it will try to find ways to escape. This is why the discovery of mutations in the BTK protein that confer resistance to Ibrutinib or so important. These can only arise in cells that have survived the BTK inhibitor long enough to figure out how to thrive under the suppressive influences of Ibrutinib.
Dose intensity can be measured in two key ways. The first is how many days you take it out of how many days you are supposed to take it. We already know in other chronic leukemias like CML, adherence to Gleevec (imatinib) is the biggest predictor of treatment success. Heck, it is even true in breast cancer with hormonal agents. Now it looks like the same is true in CLL. Sometimes side effects force you to hold therapy - but prolonged drug holds are undesirable. Patients who had drug holds in excess of 8 days were almost three times more likely to experience a disease progression (link to ASCO 2015 abstract here).
The second way dose intensity is measured reflects what dose you take daily compared to the "optimal biologic dose." There was a very compelling presentation at AACR a few months ago (I am still trying to figure out how to link to the actual poster, but here is link to the session). The study title was "Population Pharmacokinetic-Pharmacodynamic (PKPD) Modeling of Ibrutinib in Subjects With B-Cell Malignancies" by Poggesi et al. (prize to the first person who figures out how to find the actual poster). I need to get a little technical for a minute - stick with me.
As I wrote above, ibrutinib has a cool property that is unique compared to most drugs. Since it covalently (or irreversibly) binds to BTK, we can do a blood draw, isolate the CLL cells, purify the BTK protein, and look to see how many molecules of the BTK protein are "bound" to a molecule of ibrutinib. This is what we call, "receptor occupancy." The higher the occupancy, the more drug is bound to the protein, and the more the pathway is shut off.
You can then ask how many people have how much of their BTK protein "occupied" or inhibited by ibrutinib at different doses. If we set the bar pretty low at 75% occupancy, any dose above 280mg (two pills) is pretty effective. 96% of patients achieve that level of occupancy at any of those doses. that may seem good but unfortunately, that low bar means that the pathway is only 75% "turned off." It is more like a dimmer switch on the lights instead of an on/off. 75% occupied means that there is a lot of room for cells to try to discover ways to become resistant. If you set the bar much higher at 90% occupancy, the standard CLL dose of 420mg (three pills) can accomplish that in 86% of patients but only 75% of patients who take two pills and 53% of patients taking on pill. In short - dose matters. You get more complete pathway inhibition with higher doses of ibrutinib.
What we don't really know what level of pathway inhibition is optimal for CLL treatment. It is tempting to think that 100% occupancy in 100% of subjects might be much better at preventing eventual resistance - but honestly, we do not know if that might mean higher levels of side effects. How could we get there? Well, perhaps we didn't actually define the "optimal biologic dose" correctly in the original phase I study. We pretty much stopped escalating dose because it seemed to be doing what we wanted it to do in the relatively small population of patients we were studying.
I would be curious to go back and do a "dose optimization" study to see if we could modify either the dosing schedule or the actual dose taken to see if we could make ibrutinib work better than it already does. I also worked on another BTK inhibitor that is no longer in development called CC-292. We never really got it to behave as well as ibrutinib until we started giving it to patients twice daily. Other BTK programs are looking at this as well. Another way of potentially addressing such drug limitations is by adding a second drug that acts through different mechanisms. This should ONLY be done in the context of a research study. We have three such studies within the US Oncology network of sites (and here as well) including the addition of ublituximab (an updated version of rituximab), the combination of a BTK and PI3K inhibitor, or even BTK in combination with one of the new immune checkpoint inhibitors - pembrolizumab.
Doctors tend to reduce doses when there are problems. It is how we think about so many different clinical problems, that we tend to assume it is smart decision making. In my own patients, I am concerned that dose reductions or prolonged dose interruptions may be causing ibrutinib to be less effective than if we can maintain the dose intensity.
To leave a comment, click on the title of this blog post. It will open up the blog post in a separate window with a comment field at the bottom. All comments are reviewed by myself before being allowed to be posted - be patient, I'm a busy guy.
Thanks for reading.
Many of the new drugs challenge that paradigm. When treatments effectively target the specific molecular abnormality with a cancer cell we can see considerably more efficacy while at the same time reducing toxicity. This has led to the concept of "optimal biologic dose." Instead of pushing the dose to the max, you only increase the dose as far as you need to - often with substantially less side effects than the traditional therapies.
Unfortunately, "optimal biologic dose" is much harder to define than "maximum tolerated dose." It presumes that we have effective and accurate means of actually measuring what were trying to do. While it may come as a surprise to many patients, the unfortunate reality is that there is an enormous amount of human judgment as well as a paucity of clear data involved in early clinical trials. Things are not as scientifically certain in early trials compared to the level of data we have later in a drugs like cycle. Furthermore, we often need to generalize to the larger population from a very small subset of patients that are appropriate for a phase I study.
There is new data regarding the dosing of Ibrutinib that I think is really important to consider.
Most drugs inhibit enzymes in what we call a "reversible" fashion. This means that the particular target is turned off only when you have high enough levels of the drug in the blood. Ibrutinib is a little bit different, it is what we call a "covalent" inhibitor. When you swallow a pill of Ibrutinib it gets into the bloodstream and either quickly binds to the BTK protein or it gets eliminated from the body. Within just a few hours of taking a pill there is virtually no free drug in the blood. Instead, it is all bound to the BTK protein - completely shutting down that signaling pathway until the cell makes more BTK. This is very different than most oral drugs where we are trying to make sure the levels are still high enough right before you take your next dose.
When you had a sore throat as a kid, the doctor always said to be sure to take all your pills so that the bacteria didn't become resistant. It is virtually a scientific paradigm that exposing bacteria to inadequate antibiotic dosing creates resistance. The same is probably true in leukemia and lymphoma with some of the new drugs. A CLL cell that has its B-cell receptor signaling pathway completely inhibited has a hard time escaping that inhibition. If that same pathway is only partially inhibited however, it will try to find ways to escape. This is why the discovery of mutations in the BTK protein that confer resistance to Ibrutinib or so important. These can only arise in cells that have survived the BTK inhibitor long enough to figure out how to thrive under the suppressive influences of Ibrutinib.
Dose intensity can be measured in two key ways. The first is how many days you take it out of how many days you are supposed to take it. We already know in other chronic leukemias like CML, adherence to Gleevec (imatinib) is the biggest predictor of treatment success. Heck, it is even true in breast cancer with hormonal agents. Now it looks like the same is true in CLL. Sometimes side effects force you to hold therapy - but prolonged drug holds are undesirable. Patients who had drug holds in excess of 8 days were almost three times more likely to experience a disease progression (link to ASCO 2015 abstract here).
The second way dose intensity is measured reflects what dose you take daily compared to the "optimal biologic dose." There was a very compelling presentation at AACR a few months ago (I am still trying to figure out how to link to the actual poster, but here is link to the session). The study title was "Population Pharmacokinetic-Pharmacodynamic (PKPD) Modeling of Ibrutinib in Subjects With B-Cell Malignancies" by Poggesi et al. (prize to the first person who figures out how to find the actual poster). I need to get a little technical for a minute - stick with me.
As I wrote above, ibrutinib has a cool property that is unique compared to most drugs. Since it covalently (or irreversibly) binds to BTK, we can do a blood draw, isolate the CLL cells, purify the BTK protein, and look to see how many molecules of the BTK protein are "bound" to a molecule of ibrutinib. This is what we call, "receptor occupancy." The higher the occupancy, the more drug is bound to the protein, and the more the pathway is shut off.
You can then ask how many people have how much of their BTK protein "occupied" or inhibited by ibrutinib at different doses. If we set the bar pretty low at 75% occupancy, any dose above 280mg (two pills) is pretty effective. 96% of patients achieve that level of occupancy at any of those doses. that may seem good but unfortunately, that low bar means that the pathway is only 75% "turned off." It is more like a dimmer switch on the lights instead of an on/off. 75% occupied means that there is a lot of room for cells to try to discover ways to become resistant. If you set the bar much higher at 90% occupancy, the standard CLL dose of 420mg (three pills) can accomplish that in 86% of patients but only 75% of patients who take two pills and 53% of patients taking on pill. In short - dose matters. You get more complete pathway inhibition with higher doses of ibrutinib.
What we don't really know what level of pathway inhibition is optimal for CLL treatment. It is tempting to think that 100% occupancy in 100% of subjects might be much better at preventing eventual resistance - but honestly, we do not know if that might mean higher levels of side effects. How could we get there? Well, perhaps we didn't actually define the "optimal biologic dose" correctly in the original phase I study. We pretty much stopped escalating dose because it seemed to be doing what we wanted it to do in the relatively small population of patients we were studying.
I would be curious to go back and do a "dose optimization" study to see if we could modify either the dosing schedule or the actual dose taken to see if we could make ibrutinib work better than it already does. I also worked on another BTK inhibitor that is no longer in development called CC-292. We never really got it to behave as well as ibrutinib until we started giving it to patients twice daily. Other BTK programs are looking at this as well. Another way of potentially addressing such drug limitations is by adding a second drug that acts through different mechanisms. This should ONLY be done in the context of a research study. We have three such studies within the US Oncology network of sites (and here as well) including the addition of ublituximab (an updated version of rituximab), the combination of a BTK and PI3K inhibitor, or even BTK in combination with one of the new immune checkpoint inhibitors - pembrolizumab.
Doctors tend to reduce doses when there are problems. It is how we think about so many different clinical problems, that we tend to assume it is smart decision making. In my own patients, I am concerned that dose reductions or prolonged dose interruptions may be causing ibrutinib to be less effective than if we can maintain the dose intensity.
To leave a comment, click on the title of this blog post. It will open up the blog post in a separate window with a comment field at the bottom. All comments are reviewed by myself before being allowed to be posted - be patient, I'm a busy guy.
Thanks for reading.
Thursday, February 19, 2015
Syk not Sick
When a B cell (either CLL or NHL) signals through the b cell receptor - a sequence of enzymes gets activated. This starts with Syk, goes to BTK, and then onto PI3 Kinase after several steps. S-Y-K stands for "spleen tyrosine kinase"
Back in 2005 as a fellow at Stanford, I figured it might be useful to shut off this pathway, so I proposed using a drug that was being developed for nasal allergies to treat NHL. The idea was a little far fetched at the time, so I had to prove my point in the lab before we could take it to the clinic. Didn't take long for me to realize I had no business trying to be a laboratory scientist although we did present the very first abstract on this idea back in 2007 at ASCO.
Our Syk inhibitor worked ok and was the first time we ever saw a "small molecule tyrosine kinase inhibitor" work against NHL/CLL. It was presented in the plenary session at ASH and eventually published in Blood here.
Richard Miller who was the chief medical officer at Pharmacyclics at the time but also saw patients with us at Stanford worked in the same clinic as me. He saw some of the patients responding to our drug (fostamatinib) and deduced that a compound he was working on called PCI-32765 that he got for free (best deal in pharma EVER) from Celera would work even better since it went after BTK. We took a casual gentleman's bet about which was the better target. I voted for Syk, he voted for BTK. Too bad because I could be retired by now had I picked BTK. PCI-32765 became ibrutinib. We treated the first CLL patients with it here in Eugene (I had left Stanford by then). The story is nicely told in a Forbes article (linked here).
Anyhow, I always believed the problem with going after Syk was not about the target, but about the drug we were using. So when the chance came up for us to try again with a new drug, I had to jump at the chance. Enter ENTOSPLETINIB.
After working on the phase I studies of idelalisib (back when it was CAL-101), we built some really nice relationships with Gilead. They are honestly a really nice group of folks. They picked up a drug (GS-9973) and we started testing it on patients with NHL and CLL. Like most of the drugs that inhibit BCR signaling, we got a really nice signal of efficacy and tolerability in CLL. Today, our first paper on the topic was published in Blood - link here.
Entospletinib looks to have pretty good efficacy in CLL. It is a twice daily pill. You really cannot compare across studies, but some of the early numbers look a lot like idelalisib. Lots of work left to be done and the trial is still recruiting patients with CLL (trial link here). Talk to your own doctor or seek an opinion at one of the centers offering the trial.
Thanks for reading.
Back in 2005 as a fellow at Stanford, I figured it might be useful to shut off this pathway, so I proposed using a drug that was being developed for nasal allergies to treat NHL. The idea was a little far fetched at the time, so I had to prove my point in the lab before we could take it to the clinic. Didn't take long for me to realize I had no business trying to be a laboratory scientist although we did present the very first abstract on this idea back in 2007 at ASCO.
Our Syk inhibitor worked ok and was the first time we ever saw a "small molecule tyrosine kinase inhibitor" work against NHL/CLL. It was presented in the plenary session at ASH and eventually published in Blood here.
Richard Miller who was the chief medical officer at Pharmacyclics at the time but also saw patients with us at Stanford worked in the same clinic as me. He saw some of the patients responding to our drug (fostamatinib) and deduced that a compound he was working on called PCI-32765 that he got for free (best deal in pharma EVER) from Celera would work even better since it went after BTK. We took a casual gentleman's bet about which was the better target. I voted for Syk, he voted for BTK. Too bad because I could be retired by now had I picked BTK. PCI-32765 became ibrutinib. We treated the first CLL patients with it here in Eugene (I had left Stanford by then). The story is nicely told in a Forbes article (linked here).
Anyhow, I always believed the problem with going after Syk was not about the target, but about the drug we were using. So when the chance came up for us to try again with a new drug, I had to jump at the chance. Enter ENTOSPLETINIB.
After working on the phase I studies of idelalisib (back when it was CAL-101), we built some really nice relationships with Gilead. They are honestly a really nice group of folks. They picked up a drug (GS-9973) and we started testing it on patients with NHL and CLL. Like most of the drugs that inhibit BCR signaling, we got a really nice signal of efficacy and tolerability in CLL. Today, our first paper on the topic was published in Blood - link here.
Entospletinib looks to have pretty good efficacy in CLL. It is a twice daily pill. You really cannot compare across studies, but some of the early numbers look a lot like idelalisib. Lots of work left to be done and the trial is still recruiting patients with CLL (trial link here). Talk to your own doctor or seek an opinion at one of the centers offering the trial.
Thanks for reading.
Tuesday, February 17, 2015
Frontline video
Some time ago, I wrote a blog post about dying (link here). It was an in depth reflection about the choices I see people make when confronting disease that has escaped control. While the post was well received and I got a lot of positive feedback, I recognize that I barely scratched the surface of a really important topic.
I would therefore like to continue to put up a variety of multimedia topics on the post that I think do a good job diving into a very difficult topic - because the topic is strangely taboo for many doctors and patients.
A while back, I added a podcast on hospice that I thought was especially good (link here)
Now Atul Gawande has put together a frontline video. Not sure if you ever watch frontline - but it doesn't pull any punches. Atul writes regularly for the New Yorker and really has a clear voice on many important topics. The video is getting very favorable reviews - so I wanted to post a link to it from the blog. Not necessarily a happy joyful topic, but a sober view to consider (link here).
In the meantime, we ARE making huge progress against CLL and NHL. I am more excited about research than ever before. I now find myself wondering if CLL or even follicular lymphoma might become curable cancers in the next ten years with emerging technologies. Please know that there is a lot of plausible hope out there - just putting these links out there to expose something that doesn't get the attention it deserves.
Thanks for reading (and listening and viewing).
I would therefore like to continue to put up a variety of multimedia topics on the post that I think do a good job diving into a very difficult topic - because the topic is strangely taboo for many doctors and patients.
A while back, I added a podcast on hospice that I thought was especially good (link here)
Now Atul Gawande has put together a frontline video. Not sure if you ever watch frontline - but it doesn't pull any punches. Atul writes regularly for the New Yorker and really has a clear voice on many important topics. The video is getting very favorable reviews - so I wanted to post a link to it from the blog. Not necessarily a happy joyful topic, but a sober view to consider (link here).
In the meantime, we ARE making huge progress against CLL and NHL. I am more excited about research than ever before. I now find myself wondering if CLL or even follicular lymphoma might become curable cancers in the next ten years with emerging technologies. Please know that there is a lot of plausible hope out there - just putting these links out there to expose something that doesn't get the attention it deserves.
Thanks for reading (and listening and viewing).
Monday, November 10, 2014
Rituximab monotherapy in CLL
I expect this blog post is going to ruffle some feathers. I can’t wait to see the responses in CLL forum, ACOR and elsewhere.
Patterns of care databases report that during the course of CLL approximately one third of patients will receive mono-therapy with rituximab (ie. rituximab with NO OTHER CHEMOTHERAPY). In fact, it is one of the most commonly utilized therapies in the management of CLL but should almost completely disappear in light of new clinical trial data. Based upon information published within the last 6 months, I think any treatment recommendation for single agent rituximab should he held to some additional scrutiny.
I will admit that I have given this therapy a limited number of times in CLL/SLL before under circumstances where I thought it might be appropriate. In CLL/SLL I think rituximab monotherapy is mostly outdated as of late 2014. Newer drugs such as obinutuzumab and Ibrutinib or new combinations such as idelalisib with rituximab have taken the place of rituximab monotherapy and I have changed my practice patterns as a result.
I recently blogged about rituximab monotherapy in follicular lymphoma and highlighted several key papers published that show how well this immunotherapy drug works. I also blogged about how the addition of lenalidomide may alter the landscape of front line treatment in follicular / indolent lymphoma. Indeed, rituximab monotherapy in indolent NHL (follicular, marginal zone) is a good treatment and definitely appropriate in many circumstances - particularly low tumor burden disease. But what is true for some indolent lymphoma isn’t necessarily true for ALL indolent b-cell disorders.
Small lymphocytic lymphoma and chronic lymphocytic leukemia are often considered two different manifestations of the same disease. Indeed, they are often referred together as CLL/SLL and lumped in with the rest of the indolent lymphomas. But different lymphomas have different behaviors and the response to rituximab is one key difference. Unfortunately, many doctors don’t pay too close attention to this distinction.
Rituximab is often a very easy drug to administer (some uncommon exceptions apply). In most indolent lymphomas and even CLL, you can see things get better and everyone seems happy. Both doctors and patients can be lulled into a sense that they are getting good therapy when they see things going the right direction – but good can sometimes be the enemy of better and may not be best in long term.
When rituximab first came out as a new drug it was noted that it had fairly modest activity in the management of chronic lymphocytic leukemia. Response rates were lower than in follicular lymphoma and didn’t last as long. Two key papers were published in the Journal of Clinical Oncology in 2001 authored by John Byrd (linked here) and Susan O’Brien (linked here). Both of them looked at ways to increase the dose of rituximab in order to get a better response in patients with relapsed disease. Dr. Byrd's paper looked at more frequent dosing and Dr O’Brien’s paper looked at giving mega-doses. Despite these efforts the overall response rates were between 35-45% and generally lasted 8-10 months.
Two key caveats though should dampen even that modest efficacy. The first is that this was in a population that had largely not been exposed to rituximab previously. Rituximab works better in patients who have never received it before. Nowadays virtually all patients get rituximab added to their first line therapy. When their disease relapses, a sizable population is getting rituximab mono-therapy and it is less likely to work when used a second time. The second caveat is that in 2001 we had different criteria for response assessments and CT scans were not used the same way they are today. Since lots of patients have enlarged lymph nodes hanging out in their chest or abdomen that cannot be detected by physical exam, looking more closely with CT scan would influence the determination of response and progression.
To get a good estimation of how well rituximab or even ofatumumab actually works, I would suggest looking at the control arm of the recently reported studies that led to the approval of idelalisib and Ibrutinib (linked here and here respectively). In these studies patients were randomly assigned to one of the “tried and true” or one of the new drugs but looked at rituxan exposed patients and used CT scans to determine progression. In the rituximab alone arm of the idelalisib study, the lymph node response rate was only 6% and the median progression free survival was under six months. Those response rates are really lousy. In the ofatumumab alone arm of the ibrutinib study, patients didn’t fare much better.
CLL researchers look at the patterns of care data and look at the utilization of rituximab monotherapy with a measure of disdain. While in the past I might have argued back that CLL patients treated in academic centers are fundamentally different from those seen in community practice (an assertion which has good data to support). Indeed, community patients are on average older, have more medical issues, and less good baseline organ function, and several other key differences compared to patients seen in academic medical centers. In the past, I think you could have used that logic to support some utilization of rituximab monotherapy but new data sets strip that away.
So what are the key new data sets?
In previously untreated CLL, obinutuzumab is better than rituximab. These are both CD20 antibodies but obinutuzumab has a number of key modifications that make it more effective than rituximab. In a paper published late last year (linked here), the German group performed a three arm study comparing chlorambucil to chlorambucil in combination with either rituximab OR obinutuzumab. From progression free survival perspective these came in at 11, 16, and 26 months respectively with obinutuzumab the clear winner. If you only compared the chlorambucil arm to the obinutuzumab arm, you even saw an overall survival benefit (second paper to ever show this in CLL). I have heard some people argue that the better performance of obinutuzumab was just based on differences in dosing in the study. I believe that is an argument made by people who are unfamiliar with obinutuzumab (gazyva). Clinically, it is a very different drug and the differences in dosing are pretty minimal.
This study was in CLL patients that are more typical for the disease (average age 71). Of course chlorambucil is somewhat of a pariah in the US and many have asked whether it is even a necessary part of the regimen. I was recently at the International Myeloma, Lymphoma, and Leukemia conference in NY where this topic was the subject of a one hour debate (hot Friday nights in the CLL research world). Hard to debate the topic given the lack of published data in this space but our group led a large study of obinutuzumab monotherapy that was presented at ASCO (link here) and will hopefully be published soon. My take on the data: you get a little more bang for the buck when you add the chlorambucil but not clear it is worth the cost, particularly with the agents available now in the relapsed setting.
Two years of average benefit in this disease can be meaningful. It will even be more meaningful if we can apply molecular data to pull out the patients less likely to benefit as well. There is new data from two studies that suggest the presence of NOTCH1 mutations makes CD20 antibody therapy considerably less effective (FC vs FCR and Chlorambucil vs chlorambucil-ofatumumab). Not sure if it applies yet to obinutuzumab yet, but hopefully that data will come out soon. You can test for NOTCH mutations here.
The second key data set (linked here) led to the approval of idelalisib. In this study, patients received either rituximab alone or in combination with idelalisib – a twice daily, non-chemotherapy pill. The difference was striking. Instead of a nodal response rate of 4% it was 96% and the difference in progression free survival was improved by 82%. In fact the difference was so striking the study had to be terminated for ethical reasons because the difference in overall survival started becoming too obvious to ignore (which we were not expecting to be different for technical reasons attributable to cross-over study design). This was the third study ever reported to show that there could be a survival difference in CLL with a new regimen.
I fundamentally believe that there is a significantly sized population of CLL patients who are not appropriate for an aggressive chemotherapy regimen. Let’s face it, the average age at first treatment in CLL is between 71-74 years old. Many are much older. Tack on heart and lung disease or multiple other medications, arthritis, etc which is entirely common in the population and things like FCR are absolutely prohibitive and even bendamustine-rituximab can be a stretch. If a CLL patient TODAY received the recommendation for rituximab therapy alone, I think it would be hard to justify why idelalisib isn’t included (note, I do not put rituximab or ofatumumab in combination with ibrutinib outside of a clinical trial as there is some suggestion that the ibrutinib may make the antibody work less well).
The third data set (linked here) compared Ibrutinib pills to ofatumumab infusions. Here too, the differences were so striking the study had to be terminated before it was planned to do so. In clinical research you set out to conduct studies when there is a sense of “equipoise.” That means there is an honest uncertainty about the difference between two therapies that you need to prove. The difference between ofatumumab and Ibrutinib in this particular study shatters the possibility of equipoise – the differences are too overwhelming. Response rates, progression free survival, and overall survival for patients treated with ibrutinib absolutely trounced ofatumumab.
So between these three papers the justification for rituximab monotherapy in either front line or relapsed CLL disappears. In front line, obinutuzumab is better than rituximab and in relapsed disease either adding idelalisib or swapping the two for Ibrutinib improve outcomes enough to fundamentally change the paradigm.
The remaining setting where CD20 antibody therapy such as rituximab or ofatumumab is used in CLL is as a “maintenance therapy” following some other chemotherapy. There have been several recent updates in this space and I think you could make a rational argument in support of maintenance though I’m not sure this is widely adopted in CLL treatment. I have provided a few links (here and here) but will leave this discussion for another time.
To summarize:
In previously untreated CLL, I think obinutuzumab has demonstrated sufficient clinical superiority over rituximab (either monotherapy or in combination with chlorambucil) to justify the swap in most cases - there is some debate about this point but I think the argument is settled. To date, there is not enough published data to routinely combine obinutuzumab with drugs like bendamustine or fludarabine outside of a clinical trial.
In patients with relapsed CLL, adding idelalisib to rituximab makes it work a whole lot better and Ibrutinib monotherapy trounces ofatumumab. Neither rituximab nor ofatumumab look nearly as good as single agents as we had believed in the past.
I anticipate the next several years of research will be about swapping out the various parts and putting them together again. Newer antibodies will be combined with newer pills and newer pills will be used earlier and earlier in the disease. It is a new era and we are quite fortunate to be in a time period where many of the “rules” are being re-written. Patients will live longer than our standard “prognosis” dictums and maybe we will even begin see a disease once considered incurable to be curable. Throw in BCL-2 inhibitors, CAR-T cells, bi-specific antibodies, and immune checkpoint inhibitors and I hope all patients will look to join in research studies so we can move the needle more quickly.
Thanks for reading
Patterns of care databases report that during the course of CLL approximately one third of patients will receive mono-therapy with rituximab (ie. rituximab with NO OTHER CHEMOTHERAPY). In fact, it is one of the most commonly utilized therapies in the management of CLL but should almost completely disappear in light of new clinical trial data. Based upon information published within the last 6 months, I think any treatment recommendation for single agent rituximab should he held to some additional scrutiny.
I will admit that I have given this therapy a limited number of times in CLL/SLL before under circumstances where I thought it might be appropriate. In CLL/SLL I think rituximab monotherapy is mostly outdated as of late 2014. Newer drugs such as obinutuzumab and Ibrutinib or new combinations such as idelalisib with rituximab have taken the place of rituximab monotherapy and I have changed my practice patterns as a result.
I recently blogged about rituximab monotherapy in follicular lymphoma and highlighted several key papers published that show how well this immunotherapy drug works. I also blogged about how the addition of lenalidomide may alter the landscape of front line treatment in follicular / indolent lymphoma. Indeed, rituximab monotherapy in indolent NHL (follicular, marginal zone) is a good treatment and definitely appropriate in many circumstances - particularly low tumor burden disease. But what is true for some indolent lymphoma isn’t necessarily true for ALL indolent b-cell disorders.
Small lymphocytic lymphoma and chronic lymphocytic leukemia are often considered two different manifestations of the same disease. Indeed, they are often referred together as CLL/SLL and lumped in with the rest of the indolent lymphomas. But different lymphomas have different behaviors and the response to rituximab is one key difference. Unfortunately, many doctors don’t pay too close attention to this distinction.
Rituximab is often a very easy drug to administer (some uncommon exceptions apply). In most indolent lymphomas and even CLL, you can see things get better and everyone seems happy. Both doctors and patients can be lulled into a sense that they are getting good therapy when they see things going the right direction – but good can sometimes be the enemy of better and may not be best in long term.
When rituximab first came out as a new drug it was noted that it had fairly modest activity in the management of chronic lymphocytic leukemia. Response rates were lower than in follicular lymphoma and didn’t last as long. Two key papers were published in the Journal of Clinical Oncology in 2001 authored by John Byrd (linked here) and Susan O’Brien (linked here). Both of them looked at ways to increase the dose of rituximab in order to get a better response in patients with relapsed disease. Dr. Byrd's paper looked at more frequent dosing and Dr O’Brien’s paper looked at giving mega-doses. Despite these efforts the overall response rates were between 35-45% and generally lasted 8-10 months.
Two key caveats though should dampen even that modest efficacy. The first is that this was in a population that had largely not been exposed to rituximab previously. Rituximab works better in patients who have never received it before. Nowadays virtually all patients get rituximab added to their first line therapy. When their disease relapses, a sizable population is getting rituximab mono-therapy and it is less likely to work when used a second time. The second caveat is that in 2001 we had different criteria for response assessments and CT scans were not used the same way they are today. Since lots of patients have enlarged lymph nodes hanging out in their chest or abdomen that cannot be detected by physical exam, looking more closely with CT scan would influence the determination of response and progression.
To get a good estimation of how well rituximab or even ofatumumab actually works, I would suggest looking at the control arm of the recently reported studies that led to the approval of idelalisib and Ibrutinib (linked here and here respectively). In these studies patients were randomly assigned to one of the “tried and true” or one of the new drugs but looked at rituxan exposed patients and used CT scans to determine progression. In the rituximab alone arm of the idelalisib study, the lymph node response rate was only 6% and the median progression free survival was under six months. Those response rates are really lousy. In the ofatumumab alone arm of the ibrutinib study, patients didn’t fare much better.
CLL researchers look at the patterns of care data and look at the utilization of rituximab monotherapy with a measure of disdain. While in the past I might have argued back that CLL patients treated in academic centers are fundamentally different from those seen in community practice (an assertion which has good data to support). Indeed, community patients are on average older, have more medical issues, and less good baseline organ function, and several other key differences compared to patients seen in academic medical centers. In the past, I think you could have used that logic to support some utilization of rituximab monotherapy but new data sets strip that away.
So what are the key new data sets?
In previously untreated CLL, obinutuzumab is better than rituximab. These are both CD20 antibodies but obinutuzumab has a number of key modifications that make it more effective than rituximab. In a paper published late last year (linked here), the German group performed a three arm study comparing chlorambucil to chlorambucil in combination with either rituximab OR obinutuzumab. From progression free survival perspective these came in at 11, 16, and 26 months respectively with obinutuzumab the clear winner. If you only compared the chlorambucil arm to the obinutuzumab arm, you even saw an overall survival benefit (second paper to ever show this in CLL). I have heard some people argue that the better performance of obinutuzumab was just based on differences in dosing in the study. I believe that is an argument made by people who are unfamiliar with obinutuzumab (gazyva). Clinically, it is a very different drug and the differences in dosing are pretty minimal.
This study was in CLL patients that are more typical for the disease (average age 71). Of course chlorambucil is somewhat of a pariah in the US and many have asked whether it is even a necessary part of the regimen. I was recently at the International Myeloma, Lymphoma, and Leukemia conference in NY where this topic was the subject of a one hour debate (hot Friday nights in the CLL research world). Hard to debate the topic given the lack of published data in this space but our group led a large study of obinutuzumab monotherapy that was presented at ASCO (link here) and will hopefully be published soon. My take on the data: you get a little more bang for the buck when you add the chlorambucil but not clear it is worth the cost, particularly with the agents available now in the relapsed setting.
Two years of average benefit in this disease can be meaningful. It will even be more meaningful if we can apply molecular data to pull out the patients less likely to benefit as well. There is new data from two studies that suggest the presence of NOTCH1 mutations makes CD20 antibody therapy considerably less effective (FC vs FCR and Chlorambucil vs chlorambucil-ofatumumab). Not sure if it applies yet to obinutuzumab yet, but hopefully that data will come out soon. You can test for NOTCH mutations here.
The second key data set (linked here) led to the approval of idelalisib. In this study, patients received either rituximab alone or in combination with idelalisib – a twice daily, non-chemotherapy pill. The difference was striking. Instead of a nodal response rate of 4% it was 96% and the difference in progression free survival was improved by 82%. In fact the difference was so striking the study had to be terminated for ethical reasons because the difference in overall survival started becoming too obvious to ignore (which we were not expecting to be different for technical reasons attributable to cross-over study design). This was the third study ever reported to show that there could be a survival difference in CLL with a new regimen.
I fundamentally believe that there is a significantly sized population of CLL patients who are not appropriate for an aggressive chemotherapy regimen. Let’s face it, the average age at first treatment in CLL is between 71-74 years old. Many are much older. Tack on heart and lung disease or multiple other medications, arthritis, etc which is entirely common in the population and things like FCR are absolutely prohibitive and even bendamustine-rituximab can be a stretch. If a CLL patient TODAY received the recommendation for rituximab therapy alone, I think it would be hard to justify why idelalisib isn’t included (note, I do not put rituximab or ofatumumab in combination with ibrutinib outside of a clinical trial as there is some suggestion that the ibrutinib may make the antibody work less well).
The third data set (linked here) compared Ibrutinib pills to ofatumumab infusions. Here too, the differences were so striking the study had to be terminated before it was planned to do so. In clinical research you set out to conduct studies when there is a sense of “equipoise.” That means there is an honest uncertainty about the difference between two therapies that you need to prove. The difference between ofatumumab and Ibrutinib in this particular study shatters the possibility of equipoise – the differences are too overwhelming. Response rates, progression free survival, and overall survival for patients treated with ibrutinib absolutely trounced ofatumumab.
So between these three papers the justification for rituximab monotherapy in either front line or relapsed CLL disappears. In front line, obinutuzumab is better than rituximab and in relapsed disease either adding idelalisib or swapping the two for Ibrutinib improve outcomes enough to fundamentally change the paradigm.
The remaining setting where CD20 antibody therapy such as rituximab or ofatumumab is used in CLL is as a “maintenance therapy” following some other chemotherapy. There have been several recent updates in this space and I think you could make a rational argument in support of maintenance though I’m not sure this is widely adopted in CLL treatment. I have provided a few links (here and here) but will leave this discussion for another time.
To summarize:
In previously untreated CLL, I think obinutuzumab has demonstrated sufficient clinical superiority over rituximab (either monotherapy or in combination with chlorambucil) to justify the swap in most cases - there is some debate about this point but I think the argument is settled. To date, there is not enough published data to routinely combine obinutuzumab with drugs like bendamustine or fludarabine outside of a clinical trial.
In patients with relapsed CLL, adding idelalisib to rituximab makes it work a whole lot better and Ibrutinib monotherapy trounces ofatumumab. Neither rituximab nor ofatumumab look nearly as good as single agents as we had believed in the past.
I anticipate the next several years of research will be about swapping out the various parts and putting them together again. Newer antibodies will be combined with newer pills and newer pills will be used earlier and earlier in the disease. It is a new era and we are quite fortunate to be in a time period where many of the “rules” are being re-written. Patients will live longer than our standard “prognosis” dictums and maybe we will even begin see a disease once considered incurable to be curable. Throw in BCL-2 inhibitors, CAR-T cells, bi-specific antibodies, and immune checkpoint inhibitors and I hope all patients will look to join in research studies so we can move the needle more quickly.
Thanks for reading
Thursday, October 23, 2014
Lenalidomide and Rituximab in Lymphoma
In a recent post I outlined some of the important historical milestones of how we arrived at current standards of care in lymphoma. I ended my list with the advent of “immunotherapy.” Last week there was a paper published (link to article here) that
helps lay the groundwork for a paradigm change in indolent (slow/follicular) lymphoma – and I
want to highlight it here.
I think patients are instinctively drawn to the idea of
immunotherapy when they understand it.
Most clinicians use the term to describe some intervention that helps
shape the immune system to fight off a cancer rather than traditional
chemotherapy. Just about every patient I
meet asks me if there are some nutritional supplements that can “boost the immune system.” While maintaining healthy Vitamin D levels is a good candidate some of the new treatments that
are being developed are pretty fantastic.
At the most simple level, rituximab is an example of
immunotherapy. I have blogged about CD20 antibodies previously. You naturally make
antibodies to fight off bacteria and viruses.
Rituximab is merely an antibody that we give to you that fights off
lymphoma and CLL. When you give the
medicine, it binds to the outside of cancer cells and alerts the remainder of
the immune system to eliminate the cancer cells – no chemo involved.
For the last 15 years we have shown in study after study
after study that adding rituximab to just about any other sort of chemotherapy
makes that chemotherapy work better. I
have also recently blogged about giving rituximab by itself (link here).
There have also been a lot of other studies that have tried
to make better versions of rituximab. We
now have FDA approval ofatumumab and obinutuzumab which are all “CD20
antibodies.” In the case of obinutuzumab it has been shown to definitively work better than rituximab in chronic lymphocytic leukemia. There is also a
huge list of CD20 antibodies that are lingering in development or have been
killed off all together because they weren’t any better.
A different approach might be to ask if adding a second drug
can make rituximab work better. One
interesting theme that has evolved in research is the concept of “T cell pseudo-exhaustion.” Lymphocytes primarily come in three flavors (T cells, B
cells, and NK cells). Rituximab works in
part by recruiting the T/NK cells to kill the B cells. But B cells are crafty – they are able to use
cell surface receptors and micro-hormones to lull the T/NK cells to sleep – aka –
pseudo-exhaustion. It is as if the T/NK
cells identify a problem, but they have
a post thanksgiving turkey coma and can’t do anything about the
problem. We call it “pseudo” though
because it is entirely a reversible biochemical process. Give those T/NK cells a jolt of biochemical “coffee”
and now they can wake back up.
It has now been well shown in multiple laboratory studies
that lenalidomide can reverse T/NK cell pseudoexhaustion. Lenalidomide is a pill that is FDA approved
for treatment of multiple myeloma , another blood disorder called MDS, and even
mantle cell lymphoma but a handful of studies have shown it has substantial
activity in both follicular lymphoma and DLBCL.
More impressively when you give those T/NK cells a medicinal jolt and
then the rituximab helps tell them where to go, the results are pretty
spectacular.
The article I referred to at the start of this is (linked here). It reports the activity of
lenalidomide (revlimid) in combination with rituximab for previously untreated
indolent NHL. Here is the punch line, it
works extremely well.
When you use rituximab with chemotherapy for untreated
follicular lymphoma (like R-CHOP or R-Bendamustine), the overall response rate
is a health 90+% and the rate of “complete response” is about 35%. Somewhere between 50-60% of patients have
their disease still in remission at the 3 year mark (link to key article here).
When you use rituximab in combination with lenalidomide toe
overall response rate is also a healthy 90+% but the rates of complete response
are an astounding 87% in follicular lymphoma.
Furthermore the rates of three year remission are closer to 80%. If you look at rates of PET negative scans at
end of treatment (an important prognostic marker) it is virtually everyone and
looking at markers like “complete molecular response” they are extremely high.
All without chemotherapy!
A few caveats to note.
This study was a “single institution study” from the MD Anderson. In multiple prior studies things that came
out of MD Anderson didn’t pan out when tested in more diverse treatment
settings (selection bias, patient comorbidity, etc.). That said, this looks like it could herald a
paradigm change in low grade lymphoma.
So what does it take to change the status quo? For starters, insurance typically wouldn’t
cover lenalidomide in this setting because it is not yet approved for frontline
treatment. Some patients may be able to
get it paid for but it is extremely expensive so without coverage few will
probably take it. Fortunately a
prospective randomized multicenter phase III study that compares lenalidomide
and rituximab to either R-CHOP / R-Bendamustine (link here) has nearly completed accrual and
if the results from that study hold up, the drug will likely be approved in
this setting and insurance will have to cover it. If that happens, I think you will see a large
change in practice patterns as patients ask / push for non-chemo treatments
that may be better than chemo treatments.
In the meantime, there are still studies patients can
join. In PREVIOUSLY TREATED lymphoma
(including follicular, marginal zone, mantle cell) there is a study going on
where EVERYONE gets the combination of these two drugs and then there is a
randomization for the duration of lenalidomide treatment (link here).
There are also a handful of other studies using lenalidomide in lymphoma in a variety of combinations (see clinical trials webpage linked here)
When you can get the immune system to do its job, it can be
a fabulous thing.
Thanks for reading
Sunday, September 28, 2014
Immunotherapy for Indolent (low grade) Lymphoma
An academic mentor once told me, “scientific advances are a lot like a game
of baseball.” Curious, I asked him what
he meant. He shared with me, “most
advances are like getting a base hit. Doubles happen but are not terribly common, triples are
rare, home runs don’t happen all that often and genuine grand slams change the
field all together.”
As I shared with him my idea of turning off B cell receptor signaling using pills, he told me, “Jeff, it sounds like you are swinging for the fences, and for our Stanford fellows, we are happy if you just crowd the plate and get hit by a pitch…” Oh well, I suppose everything worked out fine, and I still don't really care much for baseball. I wanted to compile the history of home-runs in the field to highlight just where we are and point out where I think we are going.
If you look back over the last 60 years of advances cancer medicine, there are only a handful of clinical breakthroughs in low grade lymphoma (indolent) that fundamentally re-oriented our treatment strategies in the disease and upended the status quo of the time. It hasn’t necessarily been a story of slow and steady progress. Instead there are discrete episodes that shred through the treatment landscape and when the dust settles, the field has evolved into something new.
Cancer is a complex beast and many discoveries have only served to show us just how little we actually know. While the progress is now exponential, so too is the amount we realize we don’t know. Every so often something comes along that genuinely moves the needle and patients have longer and better lives. I am very excited about an emerging story in indolent NHL and I wanted to help put in context a story that I think we are going to hear about very soon.
Here is my short list – for the interested reader, I highly recommend the book The Emperor of All Maladies. It was written by one of my residency training classmates at MGH and has received the Pulitzer Prize. It is a fantastic read.
1) Way back in the 1940's local radiation therapy was the only treatment available. This really didn't work well in a disease that is typically "systemic." Since we didn't know much about radiation dosing, patients were burned and burned again until their disease became "radiation resistant" and they died of massive lymph node enlargement or complications from radiation.
2) In 1946 we had the introduction of "chemotherapy" which actually spun out of chemical warfare research during WWII. (The remarkable story of America’s “Second Pearl Harbor” and the birth of chemotherapy is one of the most amazing little known stories in medicine). Patients with lymphoma were the very first to be treated with modified versions of mustard gas. Responses were short-lived but merely 15 years after the introduction of penicillin the idea that “medicine” could treat cancer was born.
3) In the 1950's the drug Adriamycin was isolated from a soil sample of a 13th century Italian Castle and subsequently was shown to be effective in lymphoma. This drug became a "backbone" of many treatment strategies in lymphoma and is still commonly used today. It is the “big red” drug that makes many lymphoma patients lose their hair but is also commonly used in breast cancer, gastric cancer, sarcoma’s and other diseases.
4) For the next several decades, progress was built in many small steps. New drugs were found, developed, and tested one at a time. Vincristine was isolated from the Madagascar Periwinkle, Etoposide was isolated from the “mayapple” and so forth. Multiagent drug cocktails were assembled and tested. When you put as many drugs together as you possibly could, you got crazy names such as M-Bacod (6 drugs), Pro-Mace-Cytabomb (8 drugs), and CODOX-M-IVAC (7 drugs). While some of these were for more aggressive lymphomas, each had their loyal adherents and debates raged without much comparative data. That all ended however in 1993 CHOP (4 drugs) was declared the winner over several more "intensive" regimens.
5) In 1997 we saw the introduction of rituximab in lymphoma. This was the first time we used a therapeutic antibody (like the ones your body makes to fight the flu) to treat cancer. Rituximab administered alone has impressive single agent activity and has become increasingly utilized as monotherapy. It was also quickly added to CHOP to make the R-CHOP regimen. This was the first "chemo-immuno-therapy" regimen and led to substantial improvements in long term outcome of patients with both low grade and DLBCL. Until 2007, patterns of care data indicate that if you were going to get chemo for follicular lymphoma, 50% got R-CHOP, and another 25% got the same regimen without the Adriamycin which adds quite a punch in terms of side effects (R-CVP), and about 15% received rituximab alone.
6) In 2008, there was a US based study of a drug that had been floating around East Germany during the entire cold war yet remained unknown to western cancer doctors. This was the first that most US docs had heard of Bendamustine. The data was quite impressive for how effective the drug was compared to standard alternatives. In 2009, the German lymphoma study group initially presented data at ASH comparing bendamustine-rituximab to R-CHOP in follicular lymphoma. It was actually only published in Lancet last year. This showed improved efficacy with bendamustine, and far reduced side effects which led to the sweeping changes in patterns of care. Bendamustine with rituximab has upended practice patterns. In the last two years, US patterns of care data reveals approximately 1/3 of previously untreated follicular lymphoma patients needing treatment receive Bendamustine-Ritxuximab, 1/3 receive rituximab alone, and only about 1/5 receive R-CHOP in front line treatment and virtually nobody receives it following relapse. Fludarabine utilization is virtually gone (see attached slide presentation at the bottom of this post and my post on "How I treat follicular lymphoma).
7) As ASCO 2007, our lab at Stanford presented the first “pre-clinical” data showing that inhibition of B-Cell receptor signaling enzymes could have therapeutic effect in B cell malignancies. This theory was subsequently confirmed in a plenary session presention at ASH in 2008 utilizing the drug fostamatinib. The discussant at the time felt that the data met the criteria for “game-changing” and put it on his list of NHL history makers. While fostamatinib is no longer being actively developed, the proof of concept directly preceded / led to the exploration of ibrutinib and idelalisib in similar diseases. In heavily pretreated patients, both of these drugs have approximately 50% overall response rate (size criteria for response determination, many more actually shrink and benefit – just not enough to be considered “partial response”) and average a year of benefit for responding patients. Idelalisib was recently FDA approved in follicular lymphoma and we await data on ibrutinib in this population. While the impact in follicular lymphoma remains an evolving story, the impact in chronic lymphocytic leukemia and small lymphocytic lymphoma is nothing short of transformative.
8) I believe story 8 in indolent lymphoma will be “immunotherapy." Rarely a day goes by where I am not asked by a patient, “is there anything I can do to boost my immune system.” While my answer has always been, “not really” a number of very important new therapies are showing that harnessing the power of the immune system to attack cancer can be extremely powerful. Drugs have been either approved or are soon to be approved in melanoma, lung cancer, kidney cancer, and bladder cancer that help the immune system identify and destroy the cancer cells – without using chemotherapy. Some of these are antibodies that interfere with the “on/off” switches of the immune system. Others “re-program” T-cells using engineered viruses that can go absolutely crazy on B cells (see amazing video here). The most accessible and perhaps most exciting of these for patients with indolent lymphoma may very well be the combination of revlimid with rituximab. There are several very important studies that are poised to position this combination at the center of treatment pathways for patients with follicular lymphoma.
Nathan Fowler’s data from MD Anderson – link here (expecting updates at publication)
Nearly completed study in frontline follicular lymphoma Rev-Rituximab vs R-Chemo – link here
Open study of Rev-Ritux in relapsed follicular lymphoma – link here
I think of the combination of revlimid-rituximab (also called R2) as a road trip with a pot of coffee and a map. Rituximab helps orient the immune system to go after the cancerous b cells by coating the outside of them and serving as an alarm for the T cells (like a road map). Revlimid (lenalidomide) helps overcome what has been called T-Cell “pseudo-exhaustion” and get them to reactivate (ready for the road). B cell cancers have a remarkable ability to “put the t cells to sleep.” Whether though secretion of hormones, or actually manipulating the on/off switches of T cells, the cancerous B cells literally put the other half of the immune system into a post thanksgiving meal food coma. Revlimid acts like a cold splash of water to the face for the sleepy T cells. Not bad for a drug that really isn’t chemotherapy but is considered an “imid” for – immunomodulatory drug.
The combination has been explored in CLL. It can be so active at times that there can be problems with tumor lysis syndrome. The combination is not approved by the FDA in this setting and should be utilized very carefully due to the associated risks.
The combination has also been explored in follicular lymphoma with some pretty spectacular results… and that will be the subject of an upcoming post!
Thanks for reading
(Patterns of care data and a nice view of the Sisters volcanic range in Oregon from Mt Bachelor Ski area)
As I shared with him my idea of turning off B cell receptor signaling using pills, he told me, “Jeff, it sounds like you are swinging for the fences, and for our Stanford fellows, we are happy if you just crowd the plate and get hit by a pitch…” Oh well, I suppose everything worked out fine, and I still don't really care much for baseball. I wanted to compile the history of home-runs in the field to highlight just where we are and point out where I think we are going.
If you look back over the last 60 years of advances cancer medicine, there are only a handful of clinical breakthroughs in low grade lymphoma (indolent) that fundamentally re-oriented our treatment strategies in the disease and upended the status quo of the time. It hasn’t necessarily been a story of slow and steady progress. Instead there are discrete episodes that shred through the treatment landscape and when the dust settles, the field has evolved into something new.
Cancer is a complex beast and many discoveries have only served to show us just how little we actually know. While the progress is now exponential, so too is the amount we realize we don’t know. Every so often something comes along that genuinely moves the needle and patients have longer and better lives. I am very excited about an emerging story in indolent NHL and I wanted to help put in context a story that I think we are going to hear about very soon.
Here is my short list – for the interested reader, I highly recommend the book The Emperor of All Maladies. It was written by one of my residency training classmates at MGH and has received the Pulitzer Prize. It is a fantastic read.
1) Way back in the 1940's local radiation therapy was the only treatment available. This really didn't work well in a disease that is typically "systemic." Since we didn't know much about radiation dosing, patients were burned and burned again until their disease became "radiation resistant" and they died of massive lymph node enlargement or complications from radiation.
2) In 1946 we had the introduction of "chemotherapy" which actually spun out of chemical warfare research during WWII. (The remarkable story of America’s “Second Pearl Harbor” and the birth of chemotherapy is one of the most amazing little known stories in medicine). Patients with lymphoma were the very first to be treated with modified versions of mustard gas. Responses were short-lived but merely 15 years after the introduction of penicillin the idea that “medicine” could treat cancer was born.
3) In the 1950's the drug Adriamycin was isolated from a soil sample of a 13th century Italian Castle and subsequently was shown to be effective in lymphoma. This drug became a "backbone" of many treatment strategies in lymphoma and is still commonly used today. It is the “big red” drug that makes many lymphoma patients lose their hair but is also commonly used in breast cancer, gastric cancer, sarcoma’s and other diseases.
4) For the next several decades, progress was built in many small steps. New drugs were found, developed, and tested one at a time. Vincristine was isolated from the Madagascar Periwinkle, Etoposide was isolated from the “mayapple” and so forth. Multiagent drug cocktails were assembled and tested. When you put as many drugs together as you possibly could, you got crazy names such as M-Bacod (6 drugs), Pro-Mace-Cytabomb (8 drugs), and CODOX-M-IVAC (7 drugs). While some of these were for more aggressive lymphomas, each had their loyal adherents and debates raged without much comparative data. That all ended however in 1993 CHOP (4 drugs) was declared the winner over several more "intensive" regimens.
5) In 1997 we saw the introduction of rituximab in lymphoma. This was the first time we used a therapeutic antibody (like the ones your body makes to fight the flu) to treat cancer. Rituximab administered alone has impressive single agent activity and has become increasingly utilized as monotherapy. It was also quickly added to CHOP to make the R-CHOP regimen. This was the first "chemo-immuno-therapy" regimen and led to substantial improvements in long term outcome of patients with both low grade and DLBCL. Until 2007, patterns of care data indicate that if you were going to get chemo for follicular lymphoma, 50% got R-CHOP, and another 25% got the same regimen without the Adriamycin which adds quite a punch in terms of side effects (R-CVP), and about 15% received rituximab alone.
6) In 2008, there was a US based study of a drug that had been floating around East Germany during the entire cold war yet remained unknown to western cancer doctors. This was the first that most US docs had heard of Bendamustine. The data was quite impressive for how effective the drug was compared to standard alternatives. In 2009, the German lymphoma study group initially presented data at ASH comparing bendamustine-rituximab to R-CHOP in follicular lymphoma. It was actually only published in Lancet last year. This showed improved efficacy with bendamustine, and far reduced side effects which led to the sweeping changes in patterns of care. Bendamustine with rituximab has upended practice patterns. In the last two years, US patterns of care data reveals approximately 1/3 of previously untreated follicular lymphoma patients needing treatment receive Bendamustine-Ritxuximab, 1/3 receive rituximab alone, and only about 1/5 receive R-CHOP in front line treatment and virtually nobody receives it following relapse. Fludarabine utilization is virtually gone (see attached slide presentation at the bottom of this post and my post on "How I treat follicular lymphoma).
7) As ASCO 2007, our lab at Stanford presented the first “pre-clinical” data showing that inhibition of B-Cell receptor signaling enzymes could have therapeutic effect in B cell malignancies. This theory was subsequently confirmed in a plenary session presention at ASH in 2008 utilizing the drug fostamatinib. The discussant at the time felt that the data met the criteria for “game-changing” and put it on his list of NHL history makers. While fostamatinib is no longer being actively developed, the proof of concept directly preceded / led to the exploration of ibrutinib and idelalisib in similar diseases. In heavily pretreated patients, both of these drugs have approximately 50% overall response rate (size criteria for response determination, many more actually shrink and benefit – just not enough to be considered “partial response”) and average a year of benefit for responding patients. Idelalisib was recently FDA approved in follicular lymphoma and we await data on ibrutinib in this population. While the impact in follicular lymphoma remains an evolving story, the impact in chronic lymphocytic leukemia and small lymphocytic lymphoma is nothing short of transformative.
8) I believe story 8 in indolent lymphoma will be “immunotherapy." Rarely a day goes by where I am not asked by a patient, “is there anything I can do to boost my immune system.” While my answer has always been, “not really” a number of very important new therapies are showing that harnessing the power of the immune system to attack cancer can be extremely powerful. Drugs have been either approved or are soon to be approved in melanoma, lung cancer, kidney cancer, and bladder cancer that help the immune system identify and destroy the cancer cells – without using chemotherapy. Some of these are antibodies that interfere with the “on/off” switches of the immune system. Others “re-program” T-cells using engineered viruses that can go absolutely crazy on B cells (see amazing video here). The most accessible and perhaps most exciting of these for patients with indolent lymphoma may very well be the combination of revlimid with rituximab. There are several very important studies that are poised to position this combination at the center of treatment pathways for patients with follicular lymphoma.
Nathan Fowler’s data from MD Anderson – link here
Nearly completed study in frontline follicular lymphoma Rev-Rituximab vs R-Chemo – link here
Open study of Rev-Ritux in relapsed follicular lymphoma – link here
I think of the combination of revlimid-rituximab (also called R2) as a road trip with a pot of coffee and a map. Rituximab helps orient the immune system to go after the cancerous b cells by coating the outside of them and serving as an alarm for the T cells (like a road map). Revlimid (lenalidomide) helps overcome what has been called T-Cell “pseudo-exhaustion” and get them to reactivate (ready for the road). B cell cancers have a remarkable ability to “put the t cells to sleep.” Whether though secretion of hormones, or actually manipulating the on/off switches of T cells, the cancerous B cells literally put the other half of the immune system into a post thanksgiving meal food coma. Revlimid acts like a cold splash of water to the face for the sleepy T cells. Not bad for a drug that really isn’t chemotherapy but is considered an “imid” for – immunomodulatory drug.
The combination has been explored in CLL. It can be so active at times that there can be problems with tumor lysis syndrome. The combination is not approved by the FDA in this setting and should be utilized very carefully due to the associated risks.
The combination has also been explored in follicular lymphoma with some pretty spectacular results… and that will be the subject of an upcoming post!
Thanks for reading
(Patterns of care data and a nice view of the Sisters volcanic range in Oregon from Mt Bachelor Ski area)
Subscribe to:
Posts (Atom)